SinoMab BioScience Limited (HKG:3681)

Market Cap	2.62B +137.7%
Revenue (ttm)	6.28M +48.4%
Net Income	-158.16M
EPS	-0.15
Shares Out	1.39B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,863,600
Average Volume	5,117,740
Open	1.770
Previous Close	1.790
Day's Range	1.770 - 1.910
52-Week Range	0.990 - 3.760
Beta	0.43
RSI	71.92
Earnings Date	Mar 25, 2026

About SinoMab BioScience

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. Its product pipeline comprises SM03 (Suciraslimab), a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA); is in phase II clinical trial to treat non-Hodgkin’s lymphoma and systemic lupus erythematosus; and is in...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 61
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3681

Financial Performance

In 2024, SinoMab BioScience's revenue was 2.03 million, an increase of 48.42% compared to the previous year's 1.37 million. Losses were -185.14 million, -23.85% less than in 2023.

Financial numbers in CNY